SCHEMBL17403540

SCHEMBL17403540

COCCN(C)Cc1ccc(C(C)(C)C)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.36
▸ GRM2 Q14416 1/20 0.34
▸ SCN9A Q15858 2/20 0.33
▸ BRAF P15056 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ MAP4K4 O95819 1/20 0.33
▸ KCNA5 P22460 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ F10 P00742 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ PDCD1 Q15116 1/20 0.32
▸ CD274 Q9NZQ7 1/20 0.32
▸ TMEM97 Q5BJF2 1/20 0.32
▸ SIGMAR1 Q99720 1/20 0.32
▸ PIK3CD O00329 1/20 0.32
▸ SLC6A9 P48067 1/20 0.32
▸ HCRTR1 O43613 1/20 0.31
▸ HCRTR2 O43614 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17409825 0.80 CXCR4 (0.36) GRM2BRAFMEN1ALDH1A1KMT2A
SCHEMBL17403598 0.79 MAP4K4 (0.39) KDM4EGRM2BRAFMEN1ALDH1A1
SCHEMBL13165236 0.79 TRPV1 (0.44) KDM4ETRPV1
SCHEMBL15986728 0.78 ALDH1A1 (0.46) KDM4EGRM2BRAFMEN1ALDH1A1
SCHEMBL21419318 0.77 CYP2C19 (0.46) KDM4EALDH1A1KCNH2TSHRTRPV1
SCHEMBL15483616 0.77 HCRTR1 (0.32) ALDH1A1HCRTR1HCRTR2
SCHEMBL12449593 0.76 SIGMAR1 (0.47) KDM4EBRAFMEN1ALDH1A1KMT2A
SCHEMBL9906406 0.75 ALDH1A1 (0.37) KDM4EMEN1ALDH1A1KMT2AHCRTR1
SCHEMBL16133696 0.74 PIK3CD (0.38) KDM4EMEN1KMT2ATSHRPIK3CD
SCHEMBL18745844 0.72 TRPV1 (0.33) KDM4ESCN9AMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9433622-B2 Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms CASE WESTERN RESERVE UNIVERSITY (US) 2016-09-06 — — US disclosed
US-20160000784-A1 PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS DOMAINEX LIMITED (GB) 2016-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160000784-A1 PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS TBK1, TBKBP1, TYMS KDM4E 835/4885GRM2 3133/4885SCN9A 2874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback